NEUROSENSE proposes a novel and visionary technology resulting from the demonstration of the upstream role of arousal in the sudden unexpected death in epilepsy (SUDEP). SUDEP is a societal challenge for which there is neither prediction nor prevention. Research in the field has for long been refining classic concepts based on the cardiac, respiratory and autonomic nervous systems impairment. Our vision is different and based on the neuroendocrine processes of epileptic seizures and arousal, which are expected to be impaired in SUDEP. The NEUROSENSE project will develop the first SUDEP Medical Device (SMD) prototype supported by artificial intelligence (AI) to anticipate life-threatening seizures and trigger automatic emergency drug administration to prevent SUDEP. This represents the very first viable solution towards a societal-friendly management of epilepsy-derived mortality, thus enabling the prevention of SUDEP worldwide. This will be achieved through the combination of expertise and innovative ideas in epilepsy and SUDEP, biosensors for medical devices, animal models of epilepsy and SUDEP and mathematical modelling. To tackle the objectives of the NEUROSENSE project, a multidisciplinary group of European leading experts in key technological areas will ensure that the complete chain of value is enclosed in a multifaceted analysis. The high-risk character of this joint science and technology research is offset by the multidisciplinary nature of the Consortium, by strong and extensive preliminary data and by the high socio-economic gain resulting from its successful execution. Based in the new SMD technology, we will build a diverse portfolio of future projects that will result in a long-term benefit for people with epilepsy, their families, the economy and society.